14 news items
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
ATNM
BMY
BPTH
17 Jun 24
period (2024-2029). The report said: "Key factors propelling the growth of this market are the high incidence and prevalence of acute myeloid leukemia
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY
13 Jun 24
due to sleep disorders.
The incidences of CNS adverse reactions reported were similar in patients
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
BMY
3 Jun 24
The most common adverse reaction(s) (incidence ≥30%) in:
LBCL are fever, cytokine release
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic
oi1g05 w2gse7nqsezbdme
BMY
30 May 24
.
Adverse Reactions
The most common adverse reaction(s) (incidence ≥30
ivk606j9e8nnql2yss4rkz73yajliujw2r7ng9hxm39n10daavowl5rqy
BMY
23 May 24
. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune- mediated
r8pwk 48d99gxio36wqm2gkmt1zgep
BMY
16 May 24
) for the safety analyses. With increased exposure to Sotyktu, the exposure-adjusted incidence rates
j0d917ayzqto2w9srdke0kfxfgsuouph0
BMY
15 May 24
.
Adverse Reactions
The most common adverse reactions (incidence ≥ 30
53b4me0yrosth9aui7t1g4qvxekx8nazm nc2u8owyc840m
BMY
10 May 24
and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation
4ipkqq2am9akvwl
BMY
26 Apr 24
OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic
7goi148y9trbz1ss0 tnc06
BMY
TSVT
5 Apr 24
adverse reactions (incidence greater than or equal to 20%) include pyrexia, CRS, hypogammaglobulinemia, infections – pathogen unspecified
kuetl1o465j9pc zl29z2ex9h5tfae488qqchmdnfjim8a2i57p
BMY
2 Apr 24
Hypertension was reported in 11.4% (63/554) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4
rq4j129hx42mew6jcicz4rte h4lkc0npvb
BMY
25 Mar 24
from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF <50% in over 1500 patients, strengthening the safety profile
- Prev
- 1
- Next